VEGFA and hypertensive disorder: When infused in pregnant and non-pregnant animals, sFlt-1 elicits hypertension, proteinuria and glomerular endotheliosis, which constitutes the histopathological hallmark of pre-eclampsia.[6], [7] Similarly, targeting VEGF directly with monoclonal antibodies or indirectly via tyrosine kinase inhibitors results in a pre-eclampsia-like syndrome, characterized by hypertension and proteinuria in humans and in animal models.[2], [8], [9].